V

Voyager Therapeutics
D

VYGR

5.45000
USD
0.22
(4.21%)
Market Closed
Volume
4,670
EPS
-1
Div Yield
-
P/E
8
Market Cap
297,709,444
Related Instruments
    A
    ALKS
    0.140
    (0.47%)
    30.220 USD
    A
    ARCT
    0.260
    (1.58%)
    16.680 USD
    B
    BLUE
    -0.31000
    (-3.79%)
    7.86000 USD
    C
    CLLS
    0.05000
    (3.36%)
    1.54000 USD
    C
    CRSP
    2.740
    (6.61%)
    44.200 USD
    E
    EDIT
    0.15000
    (12.50%)
    1.35000 USD
    N
    NTLA
    1.040
    (10.45%)
    10.990 USD
    Q
    QURE
    0.390
    (2.61%)
    15.310 USD
    S
    SGMO
    0.03500
    (3.13%)
    1.15500 USD
    More
News

Title: Voyager Therapeutics

Sector: Healthcare
Industry: Biotechnology
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.